IMUX - Immunic Inc logo

IMUX

Immunic Inc

Immunic Inc develops oral small molecule therapies for chronic inflammatory and autoimmune diseases, focusing on conditions like multiple sclerosis and gastrointestinal disorders. Its pipeline includes treatments in various clinical trial phases targeting unmet patient needs.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$6today

Score Overview

1 Year
Scoreโ€”
Net Growth-7.32%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-12.39%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-154.55%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Scoreโ€”
Net Growth-118.78%
Net Trend42%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Immunic Inc fundamental performance

Between 2015 and 2025, net income went from -$ 52M to -$ 97M. Revenue increased in 0 of those 10 years; net income in 4.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 15.93โ€”
1 Year2025-08-12
$ 8.5286.97%
5 Years2021-08-12
$ 97.20-83.61%
10 Years2016-08-12
$ 2.47K-99.35%
All Time2014-04-17
$ 4.8K-99.67%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 104M$ 186M
2025$ 0.00-$ 97M$ 15M
2024$ 0.00-$ 100M$ 35M
2023$ 0.00-$ 93M$ 46M
2022$ 0.00-$ 120M$ 116M
2021$ 0.00-$ 92M$ 86M
2020$ 0.00-$ 44M$ 127M
2019$ 0.00-$ 34M$ 29M
2018$ 0.00-$ 41M$ 13M
2017$ 0.00-$ 52M$ 56M
2016$ 6K-$ 40M$ 59M
2015-$ 52M$ 83M
IPO2014-$ 47M$ 102M

Explore beyond IMUX

You're looking at Immunic Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies